Treatment of Histoplasmosis

Treatment Based on Disease Severity

• The Infectious Diseases Society of America recommends lipid formulation of amphotericin B (3.0-5.0 mg/kg daily intravenously) or amphotericin B deoxycholate (0.7-1.0 mg/kg daily) for 1-2 weeks as initial therapy for severe or moderately severe disease, followed by itraconazole (200 mg twice daily) to complete a total of 12 weeks of treatment 1, 2
• Liposomal amphotericin B has demonstrated higher response rates (88% vs 64%) and lower mortality (2% vs 13%) compared to amphotericin B deoxycholate in patients with AIDS and progressive disseminated histoplasmosis 1
• Methylprednisolone (0.5-1.0 mg/kg daily intravenously) during the first 1-2 weeks may be beneficial for patients who develop respiratory complications, hypoxemia, or significant respiratory distress 2

Treatment of Mild to Moderate Disease

• The Infectious Diseases Society of America recommends itraconazole (200 mg once or twice daily for 6-12 weeks) as the preferred treatment for mild to moderate disease 1, 3
• For patients with symptoms lasting less than 4 weeks, treatment may be unnecessary as the condition is often self-limited 2, 3

Treatment Duration Based on Disease Type

• The Infectious Diseases Society of America recommends itraconazole (200 mg once or twice daily) for at least 12 months for chronic cavitary pulmonary histoplasmosis 3
• Blood levels of itraconazole should be monitored after at least 2 weeks of therapy to ensure adequate drug exposure 2
• Relapse occurs in approximately 15% of cases 3

Special Considerations

• Hepatic enzyme levels should be measured before starting azole therapy and at 1, 2, and 4 weeks, then every 3 months during treatment 1
• Itraconazole blood levels should be monitored in cases of suspected treatment failure, concerns about absorption, drug interactions, or when adjusting dosage 4

Common Pitfalls and Caveats

• Itraconazole capsules require high gastric acidity for absorption and should be taken with food or a cola drink 1
• Patients receiving antacids, H2 blockers, or proton pump inhibitors should not use itraconazole capsules due to decreased absorption 1
• Treatment is not indicated for asymptomatic patients with healed histoplasmosis manifestations such as pulmonary nodules, mediastinal lymphadenopathy, or calcified splenic lesions 5
• Presumed ocular histoplasmosis syndrome does not respond to antifungal therapy 5, 6

Treatment of Subclinical or Progressive Subacute Histoplasmosis

Indications for Antifungal Therapy

• The Infectious Diseases Society of America recommends itraconazole (200 mg three times daily for 3 days, then 200 mg once or twice daily for 6-12 weeks) for patients with symptoms persisting beyond 1 month 7
• The Infectious Diseases Society of America indicates itraconazole therapy for patients requiring corticosteroid therapy for inflammatory complications, to prevent progressive disseminated disease due to corticosteroid-induced immunosuppression 7

When Treatment is NOT Required

• Most patients with subclinical or mild subacute histoplasmosis do not require antifungal therapy, as the condition is self-limited and resolves within 3 weeks in approximately 95% of immunocompetent cases 7
• In documented outbreaks, only 1-3.7% of patients required hospitalization, and the vast majority recovered without antifungal intervention 7

Common Pitfalls to Avoid

• The Infectious Diseases Society of America advises against treating based solely on positive antibody tests or antigen detection in patients with minimal symptoms, as these may reflect past exposure rather than active disease requiring therapy 7

When to Escalate Therapy

• Amphotericin B formulations are reserved for patients who develop moderately severe to severe acute pulmonary disease with hypoxemia or respiratory distress requiring ventilatory support 8
• Amphotericin B formulations are also reserved for patients who develop progressive disseminated disease despite observation or initial therapy 8

Management of Mild Acute Pulmonary Histoplasmosis in Children

When Antifungal Therapy Is Not Required

• In immunocompetent children with mild symptoms lasting less than 4 weeks, routine antifungal therapy is unnecessary; the disease is self‑limited and resolves within 3 weeks in about 95 % of cases. (Infectious Diseases Society of America) 9
• Outbreak investigations in school settings show ≥95 % of affected children recover within 3 weeks, with only 1–3.7 % requiring hospitalization and minimal use of antifungals. (Infectious Diseases Society of America) 9

Indications for Initiating Itraconazole

• Itraconazole should be started only if respiratory symptoms persist beyond 1 month after onset. (Infectious Diseases Society of America) 9
• Children who develop moderate‑to‑severe disease (e.g., respiratory distress, hypoxemia, or need for hospitalization) require amphotericin B rather than itraconazole. (Infectious Diseases Society of America) 9

Itraconazole Dosing for Children

• Recommended pediatric dose: 5–10 mg/kg per day divided into two doses, not exceeding 400 mg daily. (Clinical Infectious Diseases) 10
• Standard adult regimen (adapted for children when needed): 200 mg three times daily for 3 days, then 200 mg once or twice daily for 6–12 weeks. (Infectious Diseases Society of America) 9

Treatment of Disseminated Histoplasmosis (Different Clinical Scenario)

• In HIV‑infected or otherwise immunocompromised children with disseminated histoplasmosis, itraconazole at 6–8 mg/kg per day for 3–12 months has demonstrated effectiveness. (CDC MMWR Recommendations) 11

Monitoring During Itraconazole Therapy

• Obtain a serum itraconazole level after 2 weeks of treatment; target concentration ≥ 1.0 mg/mL to confirm adequate exposure. (Clinical Infectious Diseases) 10
• Observe patients for gastrointestinal adverse effects, rash, and rare hematologic toxicity (e.g., thrombocytopenia, leukopenia) while on itraconazole. (CDC MMWR Recommendations) 11

Key Clinical Distinction

• Acute pulmonary histoplasmosis in immunocompetent children is distinct from chronic pulmonary or disseminated forms; each requires different treatment indications and duration. (Infectious Diseases Society of America; Clinical Infectious Diseases) [9][10]